News

pharmaphorum17h
Replimune receives CRL on BLA for RP1 for advanced melanoma
Replimune Group, Inc – a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies – ...
Targeted Oncology1d
FDA Issues CRL for RP1 in Advanced Melanoma
Replimune faces FDA hurdles for RP1, an innovative melanoma treatment, as it seeks a path forward after receiving a complete ...
Replimune (REPL) Shares Plummet After FDA Rejects Melanoma Drug, Sparking Investor Concerns - Hagens Berman
SAN FRANCISCO, July 23, 2025 (GLOBE NEWSWIRE) -- Investors in Replimune Group, a biotechnology company focused on cancer treatments, witnessed a dramatic collapse in their holdings on July 22. Shares ...
Here’s why Iova stock surged 32% today and why the rally might not be over
Iova stock jumps 31% amid FDA setback for rival, short squeeze buzz, and rising momentum for Amtagvi melanoma therapy.
Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program
Replimune Group, Inc. faces FDA setbacks with RP1, raising financial risks and dilution concerns. Click here to find out why ...
Investor's Business Daily on MSN1d
Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock
Replimune stock cratered Tuesday after the Food and Drug Administration unexpectedly rejected its experimental melanoma ...
Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration ...
Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug
Iovance Biotherapeutics, Inc. stock faces challenges with disappointing Q1 earnings and competition. Click for why potential ...